However, the questions of whether endocrine therapy or CDK4/6 inhibitors are able to induce DNA damage, alter the chromatin landscape of DNA repair proteins and modify histones and importantly, how these might affect global transcription in ER+ breast cancer cells still remain. This evidence concerns the gene XRCC6P5 and breast cancer.